These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 2060267

  • 21. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases.
    Buss DH, Stuart JJ, Lipscomb GE.
    Am J Hematol; 1985 Dec; 20(4):365-72. PubMed ID: 3865532
    [Abstract] [Full Text] [Related]

  • 22. [Clinical characterization of essential thrombocythemia in comparison to other myeloproliferative diseases and reactive thrombocytoses].
    Zankovich R, Diehl V.
    Klin Wochenschr; 1988 Aug 01; 66(15):699-702. PubMed ID: 3172678
    [No Abstract] [Full Text] [Related]

  • 23. [Hematostatic function in myeloproliferative diseases].
    Zhu X, Pei MF, Xu M, Zhang GS.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct 01; 14(5):1013-6. PubMed ID: 17096909
    [Abstract] [Full Text] [Related]

  • 24. Thrombocytosis in children.
    Chiarello P, Magnolia M, Rubino M, Liguori SA, Miniero R.
    Minerva Pediatr; 2011 Dec 01; 63(6):507-13. PubMed ID: 22075805
    [Abstract] [Full Text] [Related]

  • 25. Blood platelet calcium content and aggregation behaviour in myeloproliferative disorders and secondary thrombocytosis.
    Mindner K, Ostermann G, Hochhaus A, Höche D, Till U.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988 Dec 01; 115(4):461-4. PubMed ID: 2465953
    [Abstract] [Full Text] [Related]

  • 26. Thrombocytosis: When is an incidental finding serious?
    Schafer AI.
    Cleve Clin J Med; 2006 Aug 01; 73(8):767-74. PubMed ID: 16913202
    [Abstract] [Full Text] [Related]

  • 27. Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia.
    Schwarz J, Pytlík R, Doubek M, Brychtová Y, Dulícek P, Campr V, Kren L, Penka M.
    Semin Thromb Hemost; 2006 Apr 01; 32(3):231-45. PubMed ID: 16673277
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Improvement of platelet aggregation abnormalities in thrombocytosis after thrombocytopheresis.
    Fabris F, Belloni M, Casonato A, Randi M, Ongaro G, Girolami A.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981 Apr 01; 108(6):853-62. PubMed ID: 6176511
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis.
    Terpos E, Verrou E, Banti A, Kaloutsi V, Lazaridou A, Zervas K.
    Leuk Res; 2007 Apr 01; 31(4):559-62. PubMed ID: 16820206
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases.
    Buss DH, Cashell AW, O'Connor ML, Richards F, Case LD.
    Am J Med; 1994 Mar 01; 96(3):247-53. PubMed ID: 8154513
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
    Murphy S, Davis JL, Walsh PN, Gardner FH.
    Arch Intern Med; 1978 Aug 01; 138(8):1251-3. PubMed ID: 277084
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Thrombocytosis in the NICU.
    Powner DJ, Hoots WK.
    Neurocrit Care; 2008 Aug 01; 8(3):471-5. PubMed ID: 18357420
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.